Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $156.60.

Several equities research analysts recently commented on SRPT shares. Mizuho boosted their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Royal Bank of Canada boosted their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. TheStreet upgraded shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Barclays boosted their target price on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $128.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 29th.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 1,200 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total value of $153,960.00. Following the sale, the chief financial officer now directly owns 39,114 shares of the company’s stock, valued at $5,018,326.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Ian Michael Estepan sold 1,200 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares of the company’s stock, valued at $5,018,326.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares in the company, valued at $3,457,550.24. The disclosure for this sale can be found here. Insiders have sold 22,096 shares of company stock worth $2,739,419 over the last ninety days. 7.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Mather Group LLC. bought a new position in Sarepta Therapeutics during the first quarter valued at about $28,000. Montag A & Associates Inc. acquired a new stake in Sarepta Therapeutics during the 3rd quarter worth about $30,000. Cary Street Partners Investment Advisory LLC raised its stake in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares in the last quarter. Principal Securities Inc. purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $26,000. Finally, GAMMA Investing LLC raised its stake in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $127.39 on Friday. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $159.89. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. The firm’s 50-day simple moving average is $126.22 and its 200 day simple moving average is $110.43. The firm has a market capitalization of $11.96 billion, a PE ratio of -20.82 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $396.80 million for the quarter, compared to analyst estimates of $387.18 million. During the same period in the previous year, the firm earned ($1.24) EPS. The business’s revenue for the quarter was up 53.6% compared to the same quarter last year. On average, equities research analysts predict that Sarepta Therapeutics will post 2.13 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.